Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Oncology

pharma-news-for-neurocrine-checkpoint-maia

Notizia - Recent Pharma, Healthcare and Biotech Happenings

FDA Approves Neurocrine’s CRENESSITY for Congenital Adrenal Hyperplasia; Checkpoint’s UNLOXCYT Approved; MAIA’s THIO Gets Rare Pediatric Disease Designation; JEMPERLI  Receives Breakthrough Therapy for Rectal Cancer; Galderma’s NEMLUVIO Approved for Atopic Dermatitis.

Explore More...
bizengri-for-nrg1-cancer-patients

Merus’ BIZENGRI: The New Face of NRG1+ Cancer Treatment After FDA Approval

imfinzi-for-ls-sclc

AstraZeneca’s IMFINZI Archives Another Milestone — Becomes the First Immunotherapy for Limited-Stage Small-cell Lung Cancer

medtech-news-for-angiodynamics-zynex-cota

Stereotaxis and Shanghai MicroPort EP Medtech Co., Ltd. Receives Approval for Magbot Robotic Magnetic Navigation Ablation Catheter From China’s NMPA; AngioDynamics NanoKnife® System Approved by FDA for Prostate Tissue Treatment; Zynex Successfully Completes Laser Pulse Oximetry Clinical Trial; COTA, PreciseDx, and Baptist Health Validate AI-Powered PreciseBreast as Equivalent to Oncotype DX; Medtronic Introduces Percept™ RC Rechargeable Neurostimulator; Crown Aesthetics Raises the Bar with the Introduction of SkinPen® Precision Elite

pharma-news-for-abbvie-gsk-novartis

AbbVie Reveals Phase III TEMPO-2 Trial Positive Topline Results; FDA Accepts GSK’s NUCALA Submission in COPD; Novartis Boosts Huntington’s Disease Development Program with PTC518 In-Licensing; Chimerix to File for Accelerated FDA Approval of Dordaviprone for H3 K27M-Mutant Diffuse Glioma; MeiraGTx Receives FDA RMAT Designation for AAV2-hAQP1 in Grade 2/3 Radiation-Induced Xerostomia Treatment

potential-of-cdk4-6-inhibitors

How CDK4/6 Inhibitors Are Changing the Cancer Treatment Paradigm?

applications-of-biochips-in-healthcare

Biochips in Healthcare: 8 Groundbreaking Applications Shaping the Industry

pharma-news-for-applied-therapeutics-alnylam-rigel

FDA Grants Fast Track for Lin BioScience’s LBS-007; Alnylam’s AMVUTTRA sNDA Under Review; FDA Approves RAPIBLYK for Atrial Fibrillation; Applied Therapeutics Receives CRL for Govorestat in Galactosemia; R289 Gets Fast Track for Lower-Risk MDS.

EGFR-NSCLC Treatment Market Dynamics

Evaluating Key Advancements and Emerging Therapies in EGFR-Non Small Cell Lung Cancer Treatment Market

Novel Insights Into The Non-Small Cell Lung Cancer Market

Novel Mutation-Targeting Therapies in the Horizon to Relieve the Global Healthcare Burden NSCLC Poses

Novel Mutation-Targeting Therapies in the Horizon to Relieve the Global Healthcare Burden NSCLC Poses

Evolving Landscape for Rare Biomarkers in Non-Small Cell Lung Cancer

recent-developments-in-nsclc-treatment

The Next Chapter in NSCLC Treatment Space: Recent Discoveries and Innovations

radioligand-therapies-reshaping-the-neuroendocrine-tumors-treatment

From Beta to Alpha Emitters: Radioligand Therapies Reshaping the Neuroendocrine Tumors Treatment Landscape

Default Blog Image

Non-Small Cell Lung Cancer Market: Treatments and Market Forecast

role-of-ai-in-cancer-diagnostics

AI in Cancer Diagnostics: Paving the Way for Early Detection and Precision Treatment

pharma-news-for-Ractigen-intellia -bridgebio

FDA Grants Orphan Drug Designation for Ractigen’s RAG-21 in ALS; Intellia’s Nexiguran RMAT for ATTR Amyloidosis; FDA Approves Acoramidis for ATTR-CM; Jazz Wins FDA Approval for Ziihera in HER2-Positive Biliary Cancer; J&J Seeks FDA Approval for Subcutaneous TREMFYA in Colitis

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Days
loader